Allison Wheeler, MD, delves into the complexities of prophylaxis for mild to moderate hemophilia A cases, exploring a patient-centric approach, situational prophylaxis during high-risk activities, and ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for its anti-tissue ...

Gene therapy for hemophilia B allowed almost three-fourths of patients to discontinue prophylactic factor IX therapy with no increase in bleeding, results of the pivotal BENEGENE-2 trial showed. The ...

Prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX) significantly reduced the risk for serious infections by approximately 50% in patients with antineutrophil cytoplasmic antibody ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved fidanacogene elaparvovec-dzkt for treatment of adults with moderate to severe hemophilia B. The ...

Please provide your email address to receive an email when new articles are posted on . Once-monthly fitusiran prophylaxis improved outcomes compared with on-demand treatment for patients with severe ...

Move over, bluebird bio: There's a new most expensive drug in the world. After an FDA endorsement Tuesday, CSL Behring and uniQure's hemophilia B gene therapy Hemgenix debuts not only as the first ...

ORLANDO, Florida ― The aggressive chemotherapy regimen given to children with acute lymphocytic leukemia (ALL) during the induction phase, which aims to push the disease into remission, also depletes ...

The COCOON trial assessed prophylactic dermatologic regimens in NSCLC patients treated with amivantamab and lazertinib, showing reduced AEs and improved quality of life. Prophylactic treatment ...